213 related articles for article (PubMed ID: 10836289)
1. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine.
Vesely C; Küfferle B; Brücke T; Kasper S
Int Clin Psychopharmacol; 2000 Jan; 15(1):57-60. PubMed ID: 10836289
[TBL] [Abstract][Full Text] [Related]
2. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
Bressan RA; Jones HM; Pilowsky LS
J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
[TBL] [Abstract][Full Text] [Related]
4. Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan.
Rizos EN; Chatziioannou S; Douzenis A; Siafakas N; Katsantoni E; Nikolaidou P; Papathanasiou M; Lykouras L
Eur Neuropsychopharmacol; 2010 Feb; 20(2):132-6. PubMed ID: 19740630
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone.
Nelson MW; Reynolds RR; Kelly DL; Conley RR
Clin Neuropharmacol; 2003; 26(6):297-8. PubMed ID: 14646608
[TBL] [Abstract][Full Text] [Related]
6. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
Emsley R; Turner HJ; Schronen J; Botha K; Smit R; Oosthuizen PP
J Clin Psychiatry; 2004 May; 65(5):696-701. PubMed ID: 15163258
[TBL] [Abstract][Full Text] [Related]
7. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine.
Khouzam HR
Depress Anxiety; 2000; 11(2):80-2. PubMed ID: 10812533
[TBL] [Abstract][Full Text] [Related]
8. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
Tauscher-Wisniewski S; Kapur S; Tauscher J; Jones C; Daskalakis ZJ; Papatheodorou G; Epstein I; Christensen BK; Zipursky RB
J Clin Psychiatry; 2002 Nov; 63(11):992-7. PubMed ID: 12444812
[TBL] [Abstract][Full Text] [Related]
9. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine.
Tauscher J; Küfferle B; Asenbaum S; Brücke T; Kasper S
Psychopharmacology (Berl); 1997 Sep; 133(1):102-5. PubMed ID: 9335088
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia.
Alptekin K; Kivircik BB
Int Clin Psychopharmacol; 2002 Sep; 17(5):263-4. PubMed ID: 12177588
[TBL] [Abstract][Full Text] [Related]
11. Tardive dyskinesia with quetiapine.
Ghelber D; Belmaker RH
Am J Psychiatry; 1999 May; 156(5):796-7. PubMed ID: 10327920
[No Abstract] [Full Text] [Related]
12. Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases.
Gourzis P; Polychronopoulos P; Papapetropoulos S; Assimakopoulos K; Argyriou AA; Beratis S
Clin Neuropharmacol; 2005; 28(4):195-6. PubMed ID: 16062102
[TBL] [Abstract][Full Text] [Related]
13. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Küfferle B; Tauscher J; Asenbaum S; Vesely C; Podreka I; Brücke T; Kasper S
Psychopharmacology (Berl); 1997 Oct; 133(4):323-8. PubMed ID: 9372530
[TBL] [Abstract][Full Text] [Related]
14. Quetiapine-associated depression in a patient with schizophrenia.
Mergui J; Jaworowski S; Lerner V
Clin Neuropharmacol; 2005; 28(3):133-5. PubMed ID: 15965312
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of dopamine receptor occupancy by [123I]IBZM-SPECT in schizophrenic patients treated with quetiapine.
Pávics L; Szekeres G; Ambrus E; Kéri S; Kovács Z; Argyelán M; Kanyó B; Csernay L; Janka Z
Nucl Med Rev Cent East Eur; 2004; 7(2):129-33. PubMed ID: 15968599
[TBL] [Abstract][Full Text] [Related]
16. Tardive dyskinesia in a patient treated with quetiapine.
Rizos E; Douzenis A; Gournellis R; Christodoulou C; Lykouras LP
World J Biol Psychiatry; 2009; 10(1):54-7. PubMed ID: 19673087
[TBL] [Abstract][Full Text] [Related]
17. Tardive dyskinesia rates with atypical antipsychotics in older adults.
Jeste DV
J Clin Psychiatry; 2004; 65 Suppl 9():21-4. PubMed ID: 15189108
[TBL] [Abstract][Full Text] [Related]
18. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
[TBL] [Abstract][Full Text] [Related]
19. ICI 204,636: a new atypical antipsychotic drug.
Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
[No Abstract] [Full Text] [Related]
20. Treatment-emergent tardive dyskinesia with quetiapine in mood disorders.
Sharma V
J Clin Psychopharmacol; 2003 Aug; 23(4):415-7. PubMed ID: 12920421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
